Intuitive Surgical: Even the Widest Moat Can Be Overpriced
Avoid using a robotic approach when valuing these shares.
We believe the market is overestimating Intuitive Surgical's (ISRG) long-term revenue and earnings growth potential. Our valuation model and company report incorporate optimistic expectations for emerging procedures even as growth moderates in core procedures. But we also expect that post-reform, U.S. hospitals operating in a tight reimbursement environment will be increasingly motivated to maximize returns on their investments, which will be reflected in slowing growth of da Vinci system sales. While we don't think that the European spending environment will remain constrained permanently, we do believe Intuitive will generally face a tougher road ahead in Europe, where providers are more hesitant to adopt new-generation technology than their U.S. counterparts. We are cognizant that Intuitive has long been a Wall Street darling, and rightfully so, given the performance of its business and shares. However, we think the market continues to extrapolate past growth forward, as evidenced by the overwhelming bullish sentiment despite the 28 forward earnings multiple and tougher comps ahead. Our $420 fair value estimate implies a 23 multiple to our 2013 earnings per share forecast, and we believe the stock is currently moderately overvalued.
We have to separate our belief in the durability of the company's competitive advantages from our take on its valuation. In our opinion, Intuitive's wide economic moat continues to stand out as one of the most durable in the sector. The company probably won't be enjoying its monopolistic position for much longer, as we estimate competitive platforms to enter the market in 2016-17, but we don't believe Intuitive will cede meaningful market share, given its plethora of clinical data and massive installed base. Enormous switching costs and a meaningful recurring revenue stream shield the firm's position and its returns on invested capital. We forecast adjusted ROICs in the 50%-plus range throughout the decade.
Alex Morozov does not own shares in any of the securities mentioned above. Find out about Morningstar’s editorial policies.
Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.
We’d like to share more about how we work and what drives our day-to-day business.
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.
How we use your information depends on the product and service that you use and your relationship with us. We may use it to:
To learn more about how we handle and protect your data, visit our privacy center.
Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.
To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.
Read our editorial policy to learn more about our process.